Mounjaro 5 mg/0.5 mL pre-filled single-dose pen

Mounjaro 5 mg/0.5 mL pre-filled single-dose pen

 Mounjaro® (tirzepatide) is a once-weekly injectable medication used to help improve blood sugar control in adults with type 2 diabetes, as part of a treatment plan that includes diet and exercise. It belongs to a novel class of medications that targets two hormone pathways—GIP and GLP-1 receptors—offering a unique approach to managing diabetes and supporting weight reduction.The 5 mg/0.5 mL pen is commonly prescribed following the initial 2.5 mg starting dose and is typically used as the first therapeutic dose in the titration schedule.

How It Works:
Tirzepatide mimics the action of two naturally occurring incretin hormones. It helps the body increase insulin release when needed, reduces the amount of sugar the liver produces, slows digestion, and decreases appetite. These combined effects improve blood glucose control and may also contribute to weight loss.

Dosage and Use:
Each pen contains 5 mg of tirzepatide in 0.5 mL of solution. It is injected subcutaneously once a week, on the same day each week, into the abdomen, thigh, or upper arm. The pen is pre-filled and ready for single use—no priming, mixing, or adjusting is necessary. Patients should rotate injection sites weekly to avoid irritation.

Storage Guidelines:
Store Mounjaro in a refrigerator between 36°F and 46°F (2°C to 8°C). If needed, it may be stored at room temperature (up to 86°F or 30°C) for up to 21 days. Avoid freezing or exposing the pen to direct sunlight.

Safety Information:
Mounjaro is not approved for use in people with type 1 diabetes or for the treatment of diabetic ketoacidosis. It should not be used by individuals with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Common side effects include nausea, vomiting, diarrhea, decreased appetite, and constipation. More serious risks, though rare, may include pancreatitis, gallbladder issues, kidney problems, and a potential risk of thyroid tumors.

Clinical Role:
The 5 mg dose is typically the first step in the maintenance phase of treatment after starting with 2.5 mg. Depending on a patient’s response and tolerance, the dose may later be increased to higher strengths such as 7.5 mg, 10 mg, or beyond.